Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity

NCT04074161 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04074161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04074161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
September 11, 2019
Completion date
May 11, 2021
Enrollment
338 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight